Data Show GATTEX Reduces Parenteral Nutrition Requirements For Short Bowel Syndrome Patients (Medical News Today)
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) has reported the presentation of Phase 3 data at the annual Digestive Disease Week (DDW) Congress on GATTEX™ (teduglutide), a novel investigational compound that may reduce dependence upon parenteral nutrition (PN) in patients with intestinal failure associated with short bowel syndrome (SBS).